ReviewCurrent gene therapy2013
Modelling human disease with pluripotent stem cells.
Review in Current gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Pluripotent stem cells for target organ developmental toxicity testing.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Refined and benchmarked homemade media for cost-effective, weekend-free human pluripotent stem cell culture.Open research Europe · 2024Article
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance.Pigment cell & melanoma research · 2023Review
- Cell models for Down syndrome-Alzheimer's disease research.Neuronal signaling · 2022Review
- Engineering skeletal muscle tissues with advanced maturity improves synapse formation with human induced pluripotent stem cell-derived motor neurons.APL bioengineering · 2021Article
- Liver Organoids: Recent Developments, Limitations and Potential.Frontiers in medicine · 2021Review
- Regulation of JAM2 Expression in the Lungs of Streptozotocin-Induced Diabetic Mice and Human Pluripotent Stem Cell-Derived Alveolar Organoids.Biomedicines · 2020Article
- Utility of Common Marmoset (Genes · 2020Review
- Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases.European cardiology · 2020Review
- Mesoderm specification and diversification: from single cells to emergent tissues.Current opinion in cell biology · 2019Review
- DeepNEU: cellular reprogramming comes of age - a machine learning platform with application to rare diseases research.Orphanet journal of rare diseases · 2019Article
- Functional Assessment of Patient-Derived Retinal Pigment Epithelial Cells Edited by CRISPR/Cas9.International journal of molecular sciences · 2018Article
- From Genotype to Phenotype: A Primer on the Functional Follow-up of Genome-Wide Association Studies in Cardiovascular Disease.Circulation. Genomic and precision medicine · 2018Article
- Mechanically patterned neuromuscular junctions-in-a-dish have improved functional maturation.Molecular biology of the cell · 2017Article
- Induced pluripotent stem cell generation from a man carrying a complex chromosomal rearrangement as a genetic model for infertility studies.Scientific reports · 2017Article
- Development of a rapid screen for the endodermal differentiation potential of human pluripotent stem cell lines.Scientific reports · 2016Article
- Transcriptomics analysis of iPSC-derived neurons and modeling of neuropsychiatric disorders.Molecular and cellular neurosciences · 2016Review
- A shift in paradigm towards human biology-based systems for cholestatic-liver diseases.The Journal of physiology · 2015Review
- Cardiac stem cells: translation to human studies.Biophysical reviews · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recent progress in the field of cellular reprogramming has opened up the doors to a new era of disease modelling, as pluripotent stem cells representing a myriad of genetic diseases can now be produced from patient tissue. These cells can be expanded and differentiated to produce a potentially limitless supply of the affected cell type, which can then be used as a tool to improve understanding of disease mechanisms and test therapeutic interventions. This process requires high levels of scrutiny and validation at every stage, but international standards for the characterisation of pluripotent cells and their progeny have yet to be established. Here we discuss the current state of the art with regard to modelling diseases affecting the ectodermal, mesodermal and endodermal lineages, focussing on studies which have demonstrated a disease phenotype in the tissue of interest. We also discuss the utility of pluripotent cell technology for the modelling of cancer and infectious disease. Finally, we spell out the technical and scientific challenges which must be addressed if the field is to deliver on its potential and produce improved patient outcomes in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.